10:33 PM
 | 
Sep 12, 2018
 |  BC Extra  |  Financial News

Galapagos follows positive RA data with $300M round

Editor's Note: This article was updated on Sep 13, 2018 at 10:45 AM PDT

On the heels of positive Phase III data for rheumatoid arthritis therapy filgotinib, Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) raised $300 million through the sale of 2.6 million ADSs at $116.50 on NASDAQ. Morgan Stanley, Citigroup, Kempen & Co., Nomura and Stifel are underwriters.

On Tuesday, Galapagos and Gilead Sciences Inc. (NASDAQ:GILD) said both once-daily 100 and 200 mg doses of filgotinib met the primary endpoint of improving ACR20 response rate at week 12 vs. placebo in the Phase III FINCH 2 trial to...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >